CN104736172A - 针对革兰氏阳性细菌的噬菌体溶素和抗生素组合 - Google Patents

针对革兰氏阳性细菌的噬菌体溶素和抗生素组合 Download PDF

Info

Publication number
CN104736172A
CN104736172A CN201380036510.8A CN201380036510A CN104736172A CN 104736172 A CN104736172 A CN 104736172A CN 201380036510 A CN201380036510 A CN 201380036510A CN 104736172 A CN104736172 A CN 104736172A
Authority
CN
China
Prior art keywords
plyss2
lysin
antibiotic
antibiotics
gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380036510.8A
Other languages
English (en)
Chinese (zh)
Inventor
R.舒奇
R.C.诺温斯基
M.维特金
H.李
B.施奈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Special Co Of Kang Tela Fick
Original Assignee
Special Co Of Kang Tela Fick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Special Co Of Kang Tela Fick filed Critical Special Co Of Kang Tela Fick
Publication of CN104736172A publication Critical patent/CN104736172A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Paints Or Removers (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201380036510.8A 2012-05-09 2013-05-09 针对革兰氏阳性细菌的噬菌体溶素和抗生素组合 Pending CN104736172A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261644944P 2012-05-09 2012-05-09
US61/644944 2012-05-09
US201261737239P 2012-12-14 2012-12-14
US61/737239 2012-12-14
PCT/US2013/040329 WO2013170015A1 (en) 2012-05-09 2013-05-09 Bacteriophage lysin and antibiotic combinations against gram positive bacteria

Publications (1)

Publication Number Publication Date
CN104736172A true CN104736172A (zh) 2015-06-24

Family

ID=49551273

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380036510.8A Pending CN104736172A (zh) 2012-05-09 2013-05-09 针对革兰氏阳性细菌的噬菌体溶素和抗生素组合

Country Status (16)

Country Link
US (5) US10813983B2 (https=)
EP (2) EP2849782B1 (https=)
JP (4) JP6608697B2 (https=)
KR (3) KR102310387B1 (https=)
CN (1) CN104736172A (https=)
AU (3) AU2013259512B2 (https=)
BR (1) BR112014027842A2 (https=)
CA (1) CA2872902A1 (https=)
DK (1) DK2849782T3 (https=)
ES (1) ES2784136T3 (https=)
HK (1) HK1211484A1 (https=)
IL (3) IL308477A (https=)
IN (1) IN2014MN02437A (https=)
MX (2) MX389127B (https=)
RU (2) RU2018121290A (https=)
WO (1) WO2013170015A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135971A (zh) * 2015-09-17 2018-06-08 抗非特公司 溶素恢复/增强在肺表面活性物质存在下由此抑制的抗生素的抗菌活性的用途
CN109152822A (zh) * 2016-05-12 2019-01-04 抗非特公司 用于评估和确定抗菌多肽的最小抑制浓度的肉汤微量稀释法
CN109668873A (zh) * 2018-12-05 2019-04-23 邢凤江 一种活载体疫苗活性检测装置及其使用方法
CN111295183A (zh) * 2017-07-10 2020-06-16 康特拉费克特公司 裂解蛋白抗菌活性的血液组分强化及其方法和用途
CN112118861A (zh) * 2018-02-26 2020-12-22 康特拉费克特公司 修饰的PlySs2溶素及其用途
CN112867398A (zh) * 2018-06-22 2021-05-28 康特拉费克特公司 溶素及其衍生物使金黄色葡萄球菌和革兰氏阳性菌对抗生素重新敏感
CN113677799A (zh) * 2019-02-05 2021-11-19 伊兰科美国公司 一种遗传修饰乳酸杆菌及其应用
CN114025783A (zh) * 2019-04-11 2022-02-08 康特拉费克特公司 治疗和预防骨和关节感染的方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018121290A (ru) 2012-05-09 2019-03-06 Контрафект Корпорейшн Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий
BR112014027818B1 (pt) 2012-05-09 2023-03-28 Contrafect Corporation Usos de composições compreendendo polipeptídeo de lisina para prevenção, ruptura ou tratamento de um biofilme bacteriano
WO2015200783A2 (en) * 2014-06-26 2015-12-30 The Rockefeller University Acinetobacter lysins
WO2016142445A2 (en) * 2015-03-12 2016-09-15 Micreos Human Health B.V. A method of treatment of a bacterial infection
CA3067542A1 (en) 2017-06-19 2018-12-27 Syddansk Universitet Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections
JP2022525914A (ja) * 2019-03-22 2022-05-20 コントラフェクト コーポレイション 感染性心内膜炎を治療する方法
CN119837855A (zh) * 2019-12-19 2025-04-18 乔治亚州大学研究基金会 用于治疗细菌感染和增强抗生素的化合物
US20230277632A1 (en) * 2020-05-19 2023-09-07 Contrafect Corporation MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA
RU2755817C1 (ru) * 2020-07-22 2021-09-21 Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" Способ снижения грамположительной микрофлоры в кишечнике птицы
KR102528412B1 (ko) * 2020-09-08 2023-05-04 클립스비엔씨 주식회사 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물
WO2022261360A1 (en) * 2021-06-09 2022-12-15 Contrafect Corporation Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria
CN115105491B (zh) * 2022-07-08 2023-12-22 东北农业大学 丝氨酸在制备抑制猪链球菌药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002959A2 (en) * 2008-07-03 2010-01-07 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8108587A (en) 1986-10-08 1988-05-06 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
CA1315229C (en) 1987-06-10 1993-03-30 Eli Lilly And Company Chromatographic purification process
EP0895534A1 (en) * 1996-04-15 1999-02-10 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US6254866B1 (en) 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US20060292135A1 (en) 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
AU2876799A (en) 1999-02-25 2000-09-14 New Horizons Diagnostics, Inc. A means for the prophylactic and therapeutic treatment of streptococcal infections
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
US6444813B2 (en) 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
JP2006513149A (ja) 2002-05-17 2006-04-20 ニュー ホライゾンズ ディアグノスティックス コーポレイション Ｂａｃｉｌｌｕｓａｎｔｈｒａｃｉｓを迅速かつ特異的に検出および殺滅するファージ関連溶菌酵素の同定
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
EP1744779A2 (en) * 2004-03-24 2007-01-24 The Rockfeller University Lytic enzymes and spore surface antigen for detection and treatment of "bacillus anthracis" bacteria and spores
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP2360248A1 (en) 2005-08-24 2011-08-24 The Rockefeller University Ply-GBS mutant lysins
WO2009029192A1 (en) 2007-08-24 2009-03-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Surfactant-based antimicrobial solution for inhalation
KR101016918B1 (ko) 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
EP2539446B1 (en) 2010-01-25 2017-11-01 Alere Scarborough Inc. A25 bacteriophage lysin
US20120271770A1 (en) * 2011-04-20 2012-10-25 Visa International Service Association Managing electronic tokens in a transaction processing system
EP2699689A4 (en) 2011-04-21 2014-12-17 Univ Utrecht Holding Bv STREPTOCOCCUS BACTERIOPHAGEN LYSINE FOR THE TREATMENT OF GRAM-POSITIVE BACTERIA IN PETS AND UTILITIES
DK2699253T3 (en) 2011-04-21 2018-07-16 Univ Rockefeller STREPTOCOCCUS BACTERYPHAGIC LYSINES FOR THE DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIES
WO2012145693A1 (en) 2011-04-22 2012-10-26 Rks Design, Inc. Instrument retention assembly
EP2702070B1 (en) 2011-04-27 2015-09-30 Lysando AG New antimicrobial agents
BR112014027818B1 (pt) 2012-05-09 2023-03-28 Contrafect Corporation Usos de composições compreendendo polipeptídeo de lisina para prevenção, ruptura ou tratamento de um biofilme bacteriano
RU2018121290A (ru) 2012-05-09 2019-03-06 Контрафект Корпорейшн Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002959A2 (en) * 2008-07-03 2010-01-07 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FENTON M ET AL: "Recombinant bacteriophage lysins as antibacterials", 《BIOENGINEERED BUGS》, vol. 1, no. 1, 31 December 2010 (2010-12-31), pages 9 - 16, XP 055194564, DOI: doi:10.4161/bbug.1.1.9818 *
JONATHAN EDWARD SCHMITZ ET AL: "Expanding the horizons of Enzybiotic Identification", 《GRADUATE SCHOOL STUDENT THESES》, 1 June 2011 (2011-06-01) *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135971A (zh) * 2015-09-17 2018-06-08 抗非特公司 溶素恢复/增强在肺表面活性物质存在下由此抑制的抗生素的抗菌活性的用途
CN109152822A (zh) * 2016-05-12 2019-01-04 抗非特公司 用于评估和确定抗菌多肽的最小抑制浓度的肉汤微量稀释法
CN109152822B (zh) * 2016-05-12 2023-12-05 抗非特公司 用于评估和确定抗菌多肽的最小抑制浓度的肉汤微量稀释法
CN111295183A (zh) * 2017-07-10 2020-06-16 康特拉费克特公司 裂解蛋白抗菌活性的血液组分强化及其方法和用途
CN112118861A (zh) * 2018-02-26 2020-12-22 康特拉费克特公司 修饰的PlySs2溶素及其用途
CN112867398A (zh) * 2018-06-22 2021-05-28 康特拉费克特公司 溶素及其衍生物使金黄色葡萄球菌和革兰氏阳性菌对抗生素重新敏感
CN109668873A (zh) * 2018-12-05 2019-04-23 邢凤江 一种活载体疫苗活性检测装置及其使用方法
CN109668873B (zh) * 2018-12-05 2021-03-16 山东恒业生物技术有限公司 一种活载体疫苗活性检测装置及其使用方法
CN113677799A (zh) * 2019-02-05 2021-11-19 伊兰科美国公司 一种遗传修饰乳酸杆菌及其应用
CN114025783A (zh) * 2019-04-11 2022-02-08 康特拉费克特公司 治疗和预防骨和关节感染的方法

Also Published As

Publication number Publication date
MX2021011843A (es) 2021-10-22
KR20210121313A (ko) 2021-10-07
JP6608697B2 (ja) 2019-11-20
JP2022058682A (ja) 2022-04-12
US10813983B2 (en) 2020-10-27
KR20150035587A (ko) 2015-04-06
IL235527B1 (en) 2023-06-01
DK2849782T3 (da) 2020-06-22
IL274832A (en) 2020-07-30
IN2014MN02437A (https=) 2015-07-10
KR20230113404A (ko) 2023-07-28
JP2015523964A (ja) 2015-08-20
RU2659208C2 (ru) 2018-06-28
HK1211484A1 (en) 2016-05-27
US20210008175A1 (en) 2021-01-14
KR102310387B1 (ko) 2021-10-13
IL235527B2 (en) 2023-10-01
RU2014149351A (ru) 2016-07-10
MX389127B (es) 2025-03-19
EP3685851A1 (en) 2020-07-29
MX2014013586A (es) 2015-06-05
BR112014027842A2 (pt) 2017-08-08
US20210128696A1 (en) 2021-05-06
WO2013170015A1 (en) 2013-11-14
RU2018121290A (ru) 2019-03-06
IL308477A (en) 2024-01-01
AU2013259512B2 (en) 2018-01-25
JP2018138045A (ja) 2018-09-06
EP2849782A4 (en) 2016-01-20
EP2849782B1 (en) 2020-03-18
AU2013259512A1 (en) 2014-12-11
IL235527A0 (en) 2015-01-29
US20150290299A1 (en) 2015-10-15
JP2020054370A (ja) 2020-04-09
AU2020233683A1 (en) 2020-10-08
US20130302306A1 (en) 2013-11-14
AU2018202845A1 (en) 2018-05-10
HK1208799A1 (en) 2016-03-18
AU2018202845B2 (en) 2020-06-18
US9889181B2 (en) 2018-02-13
EP2849782A1 (en) 2015-03-25
ES2784136T3 (es) 2020-09-22
US20180221456A1 (en) 2018-08-09
CA2872902A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
AU2018202845B2 (en) Bacteriophage lysin and antibiotic combinations against gram positive bacteria
AU2018201736B2 (en) Biofilm prevention, disruption and treatment with bacteriophage lysin
HK40033231A (en) Bacteriophage lysin and antibiotic combinations against gram positive bacteria
HK1208799B (en) Bacteriophage lysin and antibiotic combinations against gram positive bacteria

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211484

Country of ref document: HK

AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20240927

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1211484

Country of ref document: HK